70G logo

Cytophage Technologies DB:70G Stock Report

Last Price

€0.19

Market Cap

€10.9m

7D

-3.5%

1Y

n/a

Updated

27 Dec, 2024

Data

Company Financials

Cytophage Technologies Ltd.

DB:70G Stock Report

Market Cap: €10.9m

70G Stock Overview

A biotechnology company, engages in the research, development, and commercialization bacteriophage therapies to treat bacterial infections affecting human health, animal health, and food security in Canada. More details

70G fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Cytophage Technologies Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Cytophage Technologies
Historical stock prices
Current Share PriceCA$0.19
52 Week HighCA$0.24
52 Week LowCA$0.14
Beta0.25
1 Month Change-5.45%
3 Month Changen/a
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO16.82%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

70GDE BiotechsDE Market
7D-3.5%3.1%0.5%
1Yn/a-13.8%7.2%

Return vs Industry: Insufficient data to determine how 70G performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how 70G performed against the German Market.

Price Volatility

Is 70G's price volatile compared to industry and market?
70G volatility
70G Average Weekly Movement18.7%
Biotechs Industry Average Movement7.0%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.5%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 70G's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine 70G's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/an/aSteven Theriaultcytophage.com

Cytophage Technologies Ltd., a biotechnology company, engages in the research, development, and commercialization bacteriophage therapies to treat bacterial infections affecting human health, animal health, and food security in Canada. It develops poultry health products under the AviPhage name; food safety products under the PhageFend name; bovine mastitis products under the BoviPhage name; and water-soluble solution for livestock producers under the FarmPhage name. The company is headquartered in Winnipeg, Canada.

Cytophage Technologies Ltd. Fundamentals Summary

How do Cytophage Technologies's earnings and revenue compare to its market cap?
70G fundamental statistics
Market cap€10.94m
Earnings (TTM)-€5.26m
Revenue (TTM)n/a

0.0x

P/S Ratio

-2.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
70G income statement (TTM)
RevenueCA$0
Cost of RevenueCA$0
Gross ProfitCA$0
Other ExpensesCA$7.91m
Earnings-CA$7.91m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.15
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did 70G perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 15:57
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cytophage Technologies Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution